Researchers from the University of Colorado Cancer Center on the Anschutz Medical Campus have created a new way of measuring cancer lesions response to treatment that could better inform the development of new cancer drugs.
Related Articles

New Study Unravels Why COVID-19 Antibody Treatments Aren’t as Effective for New Variants
A new study published in today’s issue of Biochemistry is the first to explore the effects of multiple mutations in the evolution of SARS-CoV-2 variants. The findings can help scientists better understand the properties of […]

New School Emerges Amid Youth Mental Health Crisis
A first-of-its-kind collaboration between clinical practitioners and public school educators aims to slow an alarming trend: A dramatic rise in youth mental health disorders over the past decade with cases steadily climbing among younger age […]

Rebalance Health Launches Groundbreaking Products with Proven Clinical Efficacy in Relieving Hot Flashes, Anxiety, and Boosting Testosterone
BOULDER, Colo., May 9, 2023 /PRNewswire/ — Rebalance Health, Inc. (www.rebalancehealth.com), the health and wellness innovators that specialize in optimizing human wellness through cortisol management, have launched three new “Superceutical™” systems, high-potency natural supplements… Click […]